July 20 (Reuters) – Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm’s oncology portfolio.
(Reporting by Christy Santhosh in Bengaluru; Editing by Anil D’Silva)
Brought to you by www.srnnews.com
